PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

SATELLITE SYMPOSIA


Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2024 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Apr 03      Thu - Apr 04      Fri - Apr 05      Sat - Apr 06   

THURSDAY, APRIL 4

6:45 - 6:30 PM
EVENT/OTHER
REGISTRATION
Chicago Promenade

7:15 - 8:15 AM
SATELLITE SYMPOSIUM
READY, SET, GO! SHAPE THE FUTURE OF CARE IN VON WILLEBRAND DISEASE (SPONSORED BY OCTAPHARMA)
Chair/Organizer: Veronica Flood
Chicago Ballroom VI

Join our distinguished faculty; Dr Veronica Flood, Dr Jill Johnsen, and Dr Shveta Gupta to explore the future of care in von Willebrand disease. The panel will discuss the diagnosis of von Willebrand disease, including identification of iron deficiency and genotyping, and the importance of prophylaxis in VWD patients. The results of the WIL-31 study will be presented, the largest prospective prophylaxis study in von Willebrand disease with an on-demand run-in study as an intra-individual patient comparator. We look forward to seeing you in Chicago!



7:15

WELCOME AND INTRODUCTION
Veronica Flood.


7:20

IDENTIFYING AND ADDRESSING UNMET PATIENT NEEDS IN VWD
Veronica Flood.


7:35

INSIGHTS FROM THE LARGEST PROSPECTIVE PROPHYLAXIS STUDY IN VWD: WIL-31
Shveta Gupta.


7:50

VWD GENOTYPING: EMPOWERING PRECISE DIAGNOSIS AND PERSONALIZED CARE
Jill Johnsen.


8:05

Q&A AND CONCLUDING REMARKS.


REINFORCING 10+ YEARS OF CLINICAL TRIAL EXPERIENCE WITH A SUBCUTANEOUS PROPHYLAXIS TREATMENT, INCLUDING THE LATEST DATA IN INFANTS: JOIN THE CONVERSATION WITH DR. MIKE SILVEY (SPONSORED BY GENENTECH)
Chicago Ballroom IX-X

Please join us for an engaging program led by Dr. Mike Silvey as he shares his perspectives on managing patients with hemophilia A using a subcutaneous prophylactic treatment. The presentation will include the pivotal efficacy and safety data that is the foundation of the ongoing clinical trial program in patients with and without FVIII inhibitors, including an overview of real-world experience. Hell also share updates from the latest trial in infants and previously untreated patients. The presentation will feature brain teasers, showcase social media thats engaging the hemophilia community, and Mythbuster polls. Be sure to bring your questions to the Q&A following the program.


8:30 - 9:45 AM
PLENARY SESSION
THE RISE OF THE PATIENT ADVOCATE - IMPACTING RESEARCH, TREATMENT, AND OUTCOMES
Chair/Organizer: Lena Volland, Kristi Smock
Sheraton Ballroom IV-V


8:30

HOW THE CLUES AND PEP SURVEYS CHANGED THE MENTAL HEALTH LANDSCAPE FOR PATIENTS AND HCP'S
Rushad Patell.


8:55

THE ROLE OF SOCIAL MEDIA IN EDUCATING THE PATIENTS AND CLINICIANS
Lelise Lake.


9:20

THE ROLE OF PATIENT ADVOCACY GROUPS IN DRIVING INNOVATION
Maria Santaella.

9:45 - 10:30 AM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB

Coffee break sponsored by Spark Therapeutics, Inc.



A1. ANTICOAGULATION CLINICS


101

UNFRACTIONATED HEPARIN USE IN THE SETTING OF ACUTE PULMONARY EMBOLISM
David Scott1, Zhongyuan Chen1, Aniko Szabo1, Lindsay Hammons1, Lisa Baumann Kreuziger1, 2. 1Medical College of Wisconsin, Milwaukee, WI, USA. 2Versiti Blood Center, Milwaukee, WI


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


102

IN VIVO VOLUME ELECTRON MICROSCOPY ANALYSIS AT THE SINGLE CELL LEVEL REVEALS REGIONAL INCREASES IN PLATELET SHAPE DISPERSITY ACROSS A MOUSE, JUGULAR VEIN PUNCTURE WOUND THROMBUS
Madhavi A. Ariyarathne1, Irina D. Pokrovskaya1, Oliver S. Zhao2, Richard D. Leapman2, Maria A. Aronova2, Brian Storrie1. 1University of Arkansas for Medical Sciences, Little Rock, AR, USA. 2National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


103

LONG-TERM EFFICACY AND SAFETY WITH ORAL BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
David J Kuter1, Terry Gernsheimer2, Waleed Ghanima3, Umer Khan4, Brad Ward5, Ahmed Daak5, Nichola Cooper6. 1Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 2University of Washington Medical Center, Seattle, WA, USA. 3A, Gralum, Norway. 4Biostatistics, Sanofi, Bridgewater, NJ, USA. 5Sanofi, Cambridge, MA, USA. 6Department of Medicine, Hammersmith Hospital, London, United Kingdom


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


104

RISK FACTORS ASSOCIATED WITH VENOUS THROMBOEMBOLISM IN CHRONIC LYMPHOCYTIC LEUKEMIA
Ambarina Faiz1, Shuang Guo1, Ashwin Sridharan1, Yong Lin2, 3, Claire Philipp1. 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. 2Rutgers School of Public Health, Piscataway, NJ, USA. 3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA


105

OUTCOMES AND PREDICTORS OF IMMUNE THROMBOCYTOPENIA IN HOSPITALIZATIONS FOR ANTIPHOSPHOLIPID SYNDROME: A NATIONWIDE INPATIENT SAMPLE ANALYSIS
Michael Imeh1, Ani Gvajaia1, Chukwunonye Amaeshi2, Fidelis Uwumiro3. 1Lincoln Medical and Mental Health Centre, Bronx, NY, USA. 2Montefiore Medical Centre, Bronx, NY, USA. 3University of Benin Teaching Hospital, Benin, Nigeria


106

THE P. D1472H POLYMORPHISM IN THE VWF GENE IS COMMON IN INDIAN PATIENTS
Ritika Sharma, Manu Jamwal, Harikishen Senee, Narender Kumar, Arihant Jain, Pankaj Malhotra, Deepak Bansal, Reena Das, Jasmina Ahluwalia. Postgraduate Institute of Medical Education and Research, Chandigarh, India


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


107

IRON DEFICIENCY HAS GENERALLY NOT BEEN CONSIDERED WHEN DEFINING SEX-BASED HEMOGLOBIN REFERENCE INTERVALS: A SYSTEMATIC REVIEW
Ingrid Blydt-Hansen1, Vidushi Swarup2, Teruko Kishibe3, Carine Bekdache2, Vanessa Giuliano4, Rebecca Sampat2, Rowan Thillaye-Kerr2, Angela Weyand5, Mark Crowther6, Miranda Wozniak7, Grace H Tang8, Michelle Sholzberg8. 1Department of Internal Medicine, University of British Columbia, Vancouver, BC, Canada. 2Hematology-Oncology Clinical Research Group, Division of Hematology-Oncology, St. Michael's Hospital, Toronto, Canada, Toronto, ON, Canada. 3Health Sciences Library, St. Michaela, Toronto, ON, Canada. 4Department of Medicine, University of Toronto, Toronto, ON, Canada. 5Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA. 6Department of Medicine, McMaster University, Hamilton, ON, Canada. 7Department of Laboratory Medicine a Pathobiology, Hematological Pathology, University of Toronto, Toronto, ON, Canada. 8Departments of Medicine, and Laboratory Medicine and Pathobiology, St Michaela, Toronto, ON, Canada


108

COAGULATION PROFILE AND CLOT STIFFNESS ANALYSIS FROM COVID-19-POSITIVE PATIENTS USING A NOVEL VISCOELASTICITY TESTING TECHNOLOGY
Dimitria Bonizol Camasao1, 2+, Jose G. Munguia-Lopez1+, Anna Perez5, JosAc A. Correa3, Cedric Schmitt2, Anis Hadj Henni2, Chantal SAcguin4, Donald C. Vinh5, Showan N. Nazhat1*. 1Department of Mining and Materials Engineering, McGill University, Montreal, QC, Canada. 2Rheolution Inc, Montreal, QC, Canada. 3Department of Mathematics and Statistics, McGill University, Montreal, QC, Canada. 4Department of Medicine, Division of Hematology, McGill University Health Centre, McGill University, Montreal, QC, Canada. 5Department of Experimental Medicine, Division of Infectious Diseases, McGill University Health Centre, McGill University, Montreal, QC, Canada


109

IMPACT OF ANTICOAGULATION IN ACQUIRED HEMOPHILIA A
Heather Frazier, Sean Dougherty, Kia Salafian, Hillary Maitland. University of Virginia, Charlottesville, VA, USA


110

PRELIMINARY FINDINGS OF UTILIZING APTT ASSAY AS A SCREENING TOOL FOR LUPUS ANTICOAGULANT
Suhhyun Kim, Daniel Sabath. Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA


111

TIMELINESS OF HEMOSTATIC THERAPY ADMINISTRATION FOR PATIENTS WITH BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT
Emily Kraft, Vanessa Bourck, Yuxin Zhang, Lisa Duffett, Alan Tinmouth, Tzu-Fei Wang, Roy Khalife. Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada


112

EVALUATION OF REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH VON WILLEBRAND DISEASE TREATED PROPHYLACTICALLY WITH RECOMBINANT VON WILLEBRAND FACTOR ACROSS TREATMENT CENTERS IN THE UNITED STATES
Jonathan C Roberts1, Maissaa Janbain2, Jessica R Marden3, Sanjana Sundaresan3, Natalia Nieto4, Bethany Jones4, Jorge Caicedo4. 1Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 2Tulane University School of Medicine, New Orleans, LA, USA. 3Analysis Group, Inc, Boston, MA, USA. 4Takeda Pharmaceuticals U. S. A, Inc, Lexington, MA, USA


113

THE RELATIONSHIP BETWEEN DIFFERENT PAIN MEASURES, DEPRESSION, AND SOCIAL SUPPORT AND RACE AND ETHNICITY IN PERSONS WITH HEMOPHILIA.
Maria E Santaella, Matthew Hartnett, Luke Luckey, Cynthia D Nichols. National Bleeding Disorders Foundation, New York, NY, USA


114

BLEEDING DUET: A CASE OF SIMULTANEOUS ACQUIRED FACTOR VIII DEFICIENCY AND ACQUIRED VON WILLEBRAND SYNDROME
Richard Yu1, Mathew Strelau1, Thunisa Shanmugalingham1 , Mackenzie Bowman2, Arnaud Bonnefoy3, Paula James2, Chai Phua1. 1University of Western Ontario, Department of Hematology, London, ON, Canada. 2Queens University, Department of Hematology, Kingston, ON, Canada. 3University of Montreal, Department of Hematology, Montreal, QC, Canada


A8. ANTITHROMBOTIC THERAPY


115

THE IMPACT OF A HIGH-RISK ANTICOAGULATION PRESCRIBING STEWARDSHIP SCORING TOOL IMPLEMENTATION IN AN INPATIENT SETTING
Emma Baker1, John Lindsley1, Ian Watt1, Rakhi Naik2, Michael Streiff2, Jennifer Yui2, Kathryn Dane1. 1The Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA. 2Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA


116

DOES UNFRACTIONATED HEPARIN VERSUS LOW MOLECULAR WEIGHT HEPARIN FOR THROMBOPROPHYLAXIS REDUCE COMPLICATIONS NEAR DELIVERY?
Sophia A. Cordes, Hani Faysal, Joaquin A. Calderon, Renxi Li, Sonya T. Gelfand, Mina Felfeli, Haeun Kim, Homa K. Ahmadzia. Department of Obstetrics and Gynecology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA


117

RIVAROXABAN IN OLDER ADULTS WITH NONVALVULAR ATRIAL FIBRILLATION: POPULATION-BASED ANALYSIS IN RESPONSE TO UPDATED BEERS CRITERIA
Ghadeer Dawwas1, Adam Cuker2. 1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA. 2Department of Medicine, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA


118

MONITORING BIVALIRUDIN THERAPY USING A BIVALIRUDIN-SPECIFIC CHROMOGENIC ANTI-IIA ASSAY
Sean G Yates1, Ravi Sarode1, Sarita Paulino1, Ibrahim F Ibrahim2, Lisa K Skariah3. 1Department of Pathology, Division of Transfusion Medicine and Hemostasis, University of Texas Southwestern Medical Center, Dallas, TX, USA. 2Department of Internal Medicine, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3UT Southwestern Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas, TX, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


119

INFLUENCE OF PHARMACEUTICAL INDUSTRY ON PUBLISHED CLINICAL TRIAL RESULTS
Divyanka Kavdikar1, Siddharth Suresh1, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Arav Raghunathan1, Ishvari Mokadam1. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA


120

CLINICAL EXPERIENCE USING REGIONAL CITRATE ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY IN A NEONATE WITH ACUTE KIDNEY FAILURE: CASE REPORT
Jessica Santoyo Cueva1, Luis Ruben Miranda Ramirez1, Michelle Cecilia Arechiga Andrade1, Erendira Reyes Ramirez1. 1Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. 2Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. 3Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico. 4Instituto Pediacritica Hospital Puerta de Hierro Andares, Zapopan, Mexico

10:30 - 11:30 AM
SHORT TALKS
SHORT TALKS - COMPLICATIONS OF DISEASE AND THERAPY IN H&T
Chair/Organizer: Bethany Samuelson Bannow, Emma DeLoughery
Sheraton Ballroom I-II


10:30

EFFICACY OF RADIOTHERAPY FOR HEMOSTASIS IN TUMOR-RELATED BLEEDING
Emma P. DeLoughery, Byron Wilson, Aaron Grossberg. Oregon Health a Science University, Portland, OR, USA


10:45

OSTEOPOROSIS AND FRAGILITY FRACTURES IN HEMOPHILIA AND VON WILLEBRAND DISEASE - A LARGE NATIONAL CLAIMS DATABASE STUDY
Divyaswathi Citla Sridhar1, Brandi Dupervil2, Laura Schieve2, Sanjay Ahuja3, Marilyn Manco-Johnson4, Roshni Kulkarni5, Suchitra Acharya6, Meera Chitlur7, Patricia Tobase8, Anjali Sharathkumar9, Binh Le2, Mike Soucie2. 1University of Arkansas for Medical Sciences/ Arkansas Children's hospital, Little Rock, AR, USA. 2Centers for Disease Control and Prevention, Atlanta, GA, USA. 3Case Western Reserve University, Cleveland, OH, USA. 4Hemophilia a Thrombosis Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 5Centers for Bleeding and Clotting Disorders, Department of Pediatrics, Michigan State University, Lansing, MI, USA. 6Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, New Hyde Park, NY, USA. 7Division of Hematology/Oncology, Childrena, Detroit, MI, USA. 8University of California San Francisco, San Francisco, CA, USA. 9Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, USA


11:00

HEALTHCARE BURDEN OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED CANCER PATIENTS: NATIONALLY REPRESENTATIVE ESTIMATES USING THE LARGEST ALL-PAYER INPATIENT DATABASE IN THE UNITED STATES
Krish Khurana1, Giuseppe Maiocco2, Nareg H. Roubinian3, Mohammad Hussain2, Waqas Azhar2, Sujitha Ketineni2, Hareena Sangha4, Michael B. Streiff5, Aaron A. R. Tobian5, Ruchika Goel2, 5, 6. 1Southern Illinois School of Medicine P4P program, Springfield, IL, USA. 2Southern Illinois School of Medicine, Springfield, IL, USA. 3Vitalant Research Institute, San Francisco, CA, USA. 4University of Texas Southwestern School of Medicine, Dallas, TX, USA. 5Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6Vitalant Corporate Medical Affairs, Scottsdale, AZ, USA


11:15

HEPARIN-INDUCED THROMBOCYTOPENIA AMONG CANCER HOSPITALIZATIONS: A TEN YEAR RETROSPECTIVE STUDY
Ayobami Olafimihan1, Praise Fawehinmi2, Ekrem Turk1, Gbolahan Olatunji3, Emmanuel Kokori3, Aderinto Nicholas 4, oh youjin1, Chiamaka Nwachukwu5, Shaka Hafeez1. 1John H. Stroger Jr Hospital, Chicago, IL, USA. 2Southern Illinois University Edwardsville, Edwardsville, IL, USA. 3University of Ilorin, Ilorin, Nigeria. 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria. 5Tulane University School of Medicine, new orleans, LA, USA


SHORT TALKS - INDUSTRY BLEEDING - NO CME
Chair/Organizer: Julie Jaffray, Johnathan Morris
Chicago Ballroom VII


10:30

IMPROVED JOINT HEALTH AFTER GENE THERAPY WITH DIRLOCTOCOGENE SAMOPARVOVEC (SPK-8011) IN PEOPLE WITH HEMOPHILIA A
Benjamin Samelson-Jones1, Peter Cygan2, Stacy Croteau3, Huyen Tran4, Margaret Ragni5, Jerome Teitel6, John Rasko 7, Spencer Sullivan 8, Jill Moormeier9, Kristina Haley10, Kristen Jaworski11, Amy MacDougall11, Alexander Long 11, Savina Jaeger 11, Tiffany Chang11, Gallia Levy11. 1Division of Hematology and the Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Childrena, Philadelphia, PA, USA. 2Department of Medicine, Division of Blood and Vascular Disorders, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. 3Department of Pediatrics, Harvard Medical School, and the Division of Hematology and Oncology, Boston Childrena, Boston, MA, USA. 4Australian Centre for Blood Diseases, Monash University, Melbourne, Australia. 5Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. 6St Michael's Hospital Haemophilia Treatment Centre, University of Toronto, Toronto, ON, Canada. 7Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, and the Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia. 8Mississippi Center for Advanced Medicine, Madison, MS, USA. 9Department of Medicine, UMKC School of Medicine, Kansas City, MO, USA. 10Department of Pediatrics, Oregon Health a Science University, Portland, OR, USA. 11Spark Therapeutics, Inc, Philadelphia, PA, USA


10:45

PROPHYLACTIC TREATMENT OF ACQUIRED VON WILLEBRAND DISEASE IN NON-HUMAN PRIMATES WITH VGA039, AN ANTI-PROTEIN S MONOCLONAL ANTIBODY
Benjamin Kim, Ian Huck, Lilley Leong, Tony Byun, Aline He, Abel Silva, Joanne Chan, Young Cho, Stephen J. Moore, Graham Parry, Sandip Panicker. Vega Therapeutics, Inc, South San Francisco, CA, USA


11:00

RECOMBINANT ADAMTS13 PROPHYLAXIS IN PATIENTS WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA: INTERIM ANALYSIS FROM THE PHASE 3B CONTINUATION STUDY
Paul Coppo1, Parth Patwari2, BjAprn MellgAyrd2, Hong Li2, Marie Scully3, Masanori Matsumoto4, Jerzy Windyga5, Thomas L Ortel6, Spero Cataland7, Paul KnApbl8, Ziqiang Yu9, Ana Antun10, Sami Ibrahimi11, Doug Criger2, Linda T Wang2. 1APHP. 6a, Paris, France. 2Takeda Development Center Americas, Inc, Cambridge, MA, USA. 3University College London Hospitals NHS Foundation Trust, London, United Kingdom. 4Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Nara, Japan. 5Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 6Duke University, Durham, NC, USA. 7Department of Internal Medicine, Ohio State University, Columbus, OH, USA. 8Department of Medicine 1, Division of Hematology and Hemostasis, Medical University of Vienna, Vienna, Austria. 9National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. 10Department of Hematology and Medical Oncology, School of Medicine, Emory University, Atlanta, GA, USA. 11Department of Internal Medicine, Section of Hematology and Oncology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA


11:15

INITIAL REPORT OF PART B PHASE 1/2 EFFICACY AND SAFETY RESULTS FOR BRUTON TYROSINE KINASE INHIBITOR RILZABRUTINIB IN PATIENTS WITH RELAPSED IMMUNE THROMBOCYTOPENIA
Nichola Cooper1, A. J. Gerard Jansen2, Jiri Mayer3, Michael D Tarantino4, Remco Diab5, Brad Ward6, Ahmed Daak6, David J Kuter7. 1Hammersmith Hospital, London, United Kingdom. 2Erasmus MC, University Medical Center, Rotterdam, Netherlands. 3Masaryk University Hospital, Brno, Czech Republic. 4The Bleeding and Clotting Disorders Institute, University of Illinois College of Medicine-Peoria, Peoria, IL, USA. 5Sanofi, Rotkreuz, LU, Switzerland. 6Sanofi, Cambridge, MA, USA. 7Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


SHORT TALKS - THROMBOSIS - INNOVATIONS IN AC
Chair/Organizer: Vinai Bhagirath, Sean Quinn
Sheraton Ballroom IV-V


10:45

APIXABAN AND RIVAROXABAN VERSUS WARFARIN AS ATRIAL FIBRILLATION OR VENOUS THROMBOEMBOLISM TREATMENT IN SEVERELY OBESE PATIENTS: A MULTICENTER RETROSPECTIVE ANALYSIS
Paul Dobry1, 2, Stephanie Edwin1, Susan Szpunar3, Christopher Giuliano1, 2. 1Department of Pharmacy, Ascension St. John Hospital, Detroit, MI, USA. 2Department of Pharmacy Practice, Wayne State University, Detroit, MI, USA. 3Department of Medical Education, Ascension St. John Hospital, Detroit, MI, USA


11:00

UNRAVELING THE ANTICOAGULANT FUNCTIONS OF FV USING MONOCLONAL ANTIBODIES
Sean Quinn1, Francis Ayombil1, Matthew Bunce1, Rodney M. Camire1, 2. 1Department of Pediatrics, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 2The University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA


11:15

THE ANTICOAGULATED TRAUMA PATIENT IN THE WILDERNESS
Emma DeLoughery, Thomas DeLoughery. Oregon Health a Science University, Portland, OR, USA

11:45 - 12:45 PM
SATELLITE SYMPOSIUM
MORE THAN CARRIERS: RECOGNIZING AND MANAGING WOMEN AND GIRLS WITH HEMOPHILIA (SPONSORED BY NOVO NORDISK)
Chicago Ballroom IX-X

To highlight Novo Nordisks long-standing commitment to women and girls with rare bleeding disorders, this interactive program will discuss the unique challenges women and girls with hemophilia experience and will highlight the serious consequences that may arise in those who are not diagnosed and treated appropriately. Many women and girls are more than carriers, and they may experience added complications during menstruation, pregnancy, labor, and delivery. Practical guidance for managing hemophilia in women and girls will be presented, including available resources for providers and patients



REAL-WORLD EXPERIENCES WITH ALTUVIIIO [ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC- VON WILLEBRAND FACTOR XTEN FUSION PROTEIN]: A FIRST-IN-CLASS TREATMENT OPTION (SPONSORED BY SANOFI)
Chicago Ballroom VI

Join us for a conversation about the mechanism of extension, pharmacokinetics, efficacy, dosing and safety information from the XTEND-1 clinical trial, as well as real-world clinical cases with ALTUVIIIO. This presentation will feature a live patient perspective.


12:45 - 1:30 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


201

LONGITUDINAL CHANGES IN HEALTH-RELATED QUALITY OF LIFE (HRQL) DURING ANTICOAGULATION THERAPY IN CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM TREATMENT
Taylor A Hopper1, Eva Ordonez Mazariegos2, Andrea Jimena Morales Arteaga3, Cristhiam M Rojas Hernandez2. 1The University of Texas Health Science Center at Houston, Houston, TX, USA. 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


202

PLATELET INDICES IN HEALTHY PREGNANCIES
Laura M. Dionisio, Giovani M. Favero. State University of Ponta Grossa, Ponta Grossa, Brazil


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


203

PREVALENCE AND OUTCOMES OF HEPARIN-INDUCED THROMBOCYTOPENIA IN INFLAMMATORY BOWEL DISEASE: A DECADE STUDY
Ayobami Olafimihan1, Ekrem Turk1, Praise fawehinmi2, Gbolahan Olatunji3, Emmanuel Kokori3, Aderinto Nicholas 4, Alejandro Vallejo1, Nkechi Akata5, Shaka Hafeez1. 1John H. Stroger Jr Hospital, Chicago, IL, USA. 2Southern Illinois University Edwardsville, Edwardsville, IL, USA. 3University of Ilorin, Ilorin, Nigeria. 4Ladoke Akintola University of Technology, Ogbomosho, Nigeria. 5Meharry Medical College, Nashville, TN, USA


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


204

FIXED-DOSING OF 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF ANTICOAGULATION: EVALUATING THE EFFECTIVENESS, SAFETY, AND COST SAVINGS
Amer Al Homssi1, Ryan Lokkesmoe1, Ryan Powers1, Benjamin Jung2, Lisa Baumann Kreuziger3. 1Medical College of Wisconsin, Milwaukee, WI, USA. 2Froedtert Health, Milwaukee, WI, USA. 3Versiti Blood Research Institute, Milwaukee, WI, USA


205

STRUCTURED EDUCATION FOR NEWLY DIAGNOSED PERSONS WITH VON WILLEBRAND DISEASE: A HEMOPHILIA TREATMENT CENTER QUALITY IMPROVEMENT PROJECT ABSTRACT
Dominique N. Barclay, Sarah E. Gonzales, Marsha Hurn, Amanda Kilgore, Jesla Ryan, Jonathan C. Roberts, Michael D. Tarantino. Bleeding and Clotting Disorders Institute, Peoria, IL, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


206

SAFETY AND EFFICACY OF THE ANTI-TISSUE FACTOR PATHWAY INHIBITOR MARSTACIMAB IN PARTICIPANTS WITH SEVERE HEMOPHILIA WITHOUT INHIBITORS: RESULTS FROM THE PHASE 3 BASIS TRIAL AND ONGOING LONG-TERM EXTENSION STUDY
Suchitra S. Acharya1, Davide Matino2, Andrew Palladino3, Eunhee Hwang3, Regina McDonald4, Carrie Turich Taylor5, John Teeter5. 1Cohen Children's Medical Center, Northwell Hemostasis and Thrombosis Center, Northwell Health, New Hyde Park, NY, USA. 2McMaster University, 237 Barton St. East, Hamilton, ON, Canada. 3Pfizer Inc, Collegeville, PA, USA. 4Pfizer Inc, New York, NY, USA. 5Pfizer Inc, Groton, CT, USA


207

EFFICACY AND SAFETY OF EPTACOG BETA FOR BLEED TREATMENT IN ADULTS AND ADOLESCENTS WITH HEMOPHILIA B AND INHIBITORS DURING PERSEPT 1
Meera Chitlur1, Yasmina Abajas2, Suchitra Acharya3, Sanjay Ahuja4, Jonathan Bernstein5, Elizabeth Bowhay-Carnes6, Brandon Hardesty7, Jonathan C. Roberts8, 9, Vanessa Salinas10, Craig Seaman11, Robert Sidonio Jr. 12, Daniel Bonzo13, Jim Phipps14, Thomas Wilkinson15, Guy Young16. 1Central Michigan University College of Medicine/Childrena, Detroit, NY, USA. 2Hemophilia and Thrombosis Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3Cohen Childrena, New Hyde Park, NY, USA. 4Rainbow Babies a Childrena, Cleveland, OH, USA. 5Hemophilia Center of Central Pennsylvania, Hershey Medical Center, Hershey, PA, USA. 6UT Health San Antonio, San Antonio, TX, USA. 7Indiana Hemophilia a Thrombosis Center, Indianapolis, IN, USA. 8Bleeding a Clotting Disorders Institute, Peoria, IL, USA. 9Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL, USA. 10Center for Inherited Blood Disorders, Orange, CA, USA. 11Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. 12Aflac Cancer and Blood Disorders Center and Emory University, Atlanta, GA, USA. 13LFB-USA, Inc, Framingham, MA, USA. 14HEMA Biologics, LLC, Louisville, KY, USA. 15GLOVAL LLC, Broomfield, CO, USA. 16Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA


208

ACCESS TO FACTOR VIII AND FACTOR IX TO PERSONS WITH HEMOPHILIA IN ARKANSAS: A QUALITY IMPROVEMENT STUDY
Divyaswathi Citla-Sridhar1, 2, Kara Burge2, Jean Aroom3, Justine Kaplan3, Shelley Crary1, 2. 1University of Arkansas for Medical Sciences, Little Rock, AR, USA. 2Arkansas Childrena, Little Rock, AR, USA. 3American Thrombosis and Hemostasis Network, Rochester, NY, USA


209

DISEASE BURDEN, QUALITY OF LIFE, AND TREATMENT PATTERNS IN PATIENTS WITH HEREDITARY FACTOR X DEFICIENCY: ANALYSIS OF DATA FROM THE HEREDITARY FACTOR X DEFICIENCY IN AMERICA SURVEY
Kim Clark1, Denise A. Garner2, Amy Wu2, Lorie Mody2, Jaymin Patel2, Brian Branchford3. 1Kedrion Biopharma, INC, Fort Lee, NJ, USA. 2AESARA, INC, Chapel Hill, NC, USA. 3Versiti Blood Research Institute, Medical College of Wisconsin, and Children's Wisconsin, Milwaukee, WI, USA


210

ELEVATED PROTEIN C IS PROTECTIVE AGAINST POST THROMBOTIC SYNDROME
Zijun He1, Vivian Thompson1, Dianne Thornhill1, Rick Shearer1, Christine Baird2, Marilyn Manco-Johnson1. 1University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 2University of Colorado Anschutz Medical Campus Research Laboratory, Aurora, CO, USA


211

PROPHYLACTIC OR POST-TRAUMATIC TREATMENT OF HYPOFIBRINOGENEMIA AND DYSFIBRINOGENEMIA WITH FIBRGYA IN EIGHT CLINICAL CASES
Jessica N. Mistretta, Kristin T. Ansteatt, Michael D. Tarantino. Bleeding and Clotting Disorder Institute, Peoria, IL, USA


212

REAL-WORLD USE OF RECOMBINANT FACTOR IX FUSION PROTEIN IN PREVIOUSLY UNTREATED PATIENTS WITH CONGENITAL HEMOPHILIA B FROM THE ATHN 8 STUDY
Courtney D. Thornburg1, Martin Chandler2, Lynn Malec3, Matthew Manuel2, Carrie O'Neill2, Michael Recht4, 5, Elizabeth Taggart2, Hongseok Kim6, Vidhi Desai6, Hiren Shah6, Shannon L. Carpenter7. 1Rady Childrena, San Diego, CA, USA. 2American Thrombosis and Hemostasis Network, Rochester, NY, USA. 3Versiti Blood Research Institute, Waukesha, WI, USA. 4Yale University School of Medicine, New Haven, CT, USA. 5National Bleeding Disorders Foundation, New York, NY, USA. 6CSL Behring, King of Prussia, PA, USA. 7Childrena, Kansas City, MO, USA


213

THE EFFECT OF BUDD-CHIARI SYNDROME (BCS) IN HOSPITALIZED HEPATOCELLULAR CARCINOMA PATIENTS (HCC): A NATIONWIDE ANALYSIS.
Ekrem G Turk, Ayobami Olafimihan, Khaldun Obeidat, Youjin Oh, Lina James, Angelo Caputi Zuniga, Alejandro Vallejo. John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA


A8. ANTITHROMBOTIC THERAPY


215

ANTI-FACTOR XI ANTIBODIES TARGETING THE APPLE 2 DOMAIN AND THE CATALYTIC DOMAIN EXERT DISTINCT IN VITRO INHIBITORY PROFILES ON COAGULATION FUNCTION
Dan Chalothorn, KehDih Lai, Weizhen Wu, Holly Sorenson, George Ehrlich, Ashique Rafique, Ishita Chatterjee, Kei Saotome, Matthew Franklin, Lori Morton. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA


216

ANTITHROMBOSIS STEWARDSHIP AS A KEY DRIVER WITHIN A VTE CENTER OF EXCELLENCE - AMBITION INVESTIGATORS
Angela M. Martoccia Grabazs, Preeyaporn Sarangarm, Sundeep S. Guliani, Jonathan L. Marinaro, Allison E. Burnett. University of New Mexico Hospital, Albuquerque, NM, USA


217

ANTICOAGULATION STEWARDSHIP: APPROPRIATE USE OF APIXABAN AND RIVAROXABAN FACTOR XA LEVELS IN THE EMERGENCY DEPARTMENT
Firas Quran, Sara Zochert, Michael Gulseth, Alicia Martin. Sanford USD Medical Center and Hospital, Sioux Falls, SD, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


218

CELLULAR INDICES OF DVT
Priyanka Kavdikar1, Ragini Mohan1, Neha Thomas1, 3, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Nysha Reddy1. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA. 3University of Westminster, London, United Kingdom


219

ARE MEDICAL LEARNERS ADEPT AT RECOGNIZING HEAVY VAGINAL BLEEDING?
Fartoon M Siad1, Andrea Lausman2, Filomena Meffe2, Carolyn Snider3, Martina Trinkaus1, 4, Michelle Sholzberg1, 4. 1Department of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Obstetrics and Gynecology, Toronto, ON, Canada. 3Division of Emergency Medicine, Toronto, ON, Canada. 4Division of Hematology/Oncology, St. Michaela, Toronto, ON, Canada

1:30 - 3:00 PM
HEMOSTASIS
IDENTIFICATION AND MANAGEMENT OF ACQUIRED BLEEDING IN THE ACUTE CARE SETTING
Chair/Organizer: Bethany Samuelson Bannow, Roy Khalife
Sheraton Ballroom I-II


1:30

REVIEW OF AQUIRED FACTOR DEFICIENCIES
Davide Matino.


2:00

LABORATORY TOOLS TO IDENTIFY ACQUIRED COAGULATION FACTOR ABNORMALITIES
Kristi Smock.


2:30

MANAGEMENT CONSIDERATIONS IN THE SURGICAL SETTING OF SUSPECTED AQUIRED FACTOR DEFICIENCIES
Rebecca Kruse-Jarres.

1:30 - 3:00 PM
THROMBOSIS / LABORATORY
TAKING THE RESULT TO THE PATIENT - LABORATORY CONSIDERATIONS IN THROMBOSIS
Chair/Organizer: William Dager, Leo Brandao
Chicago Ballroom VII


1:30

LABORATORY CONSIDERATIONS ON DOAC LEVELS (INCLUDING PRECISION AND WHAT WE'VE LEARNED FROM EXTERNAL QA; COMMENT ON ANDEXANET)
Jim Zehnder.


2:00

DOAC - WHEN TO MEASURE LEVELS AND HOW TO INTERPRET: ON-TREATMENT VS THERAPEUTIC RANGE
Deb Siegal.


2:30

ADVANCES IN TESTING FOR APS - BEYOND SAPPORO (TITRES, ISOTYPES, NON-CRITERIA ANTIBODIES)
Tom Ortel.

1:30 - 3:00 PM
BASIC SCIENCE
UNBIASED TECH APPROACHES FOR HEMATOLOGICAL DISCOVERIES
Chair/Organizer: Jordan Shavit, Laura Haynes
Sheraton Ballroom IV-V


1:30

DEEP MUTATIONAL SCANNING TO PROBE FUNCTION OF COAGULATION PROTEINS
Laura Haynes.


2:00

GENETIC ENGINEERING OF MEGAKARYOCYTES TO UNCOVER FUNCTIONS OF PLATELET PROTEINS
Jesse Rowley.


2:30

MASS SPECTROMETRY GLYCOMICS AND DETERMINATION OF GPIB GLYCOSITES
Marie Hollenhorst .

3:00 - 5:00 PM
POSTER SESSION
ONLINE POSTER SESSION
On-Demand/Online


THE ROLE OF FIBRINOGEN IN CHANGING THE HEMOSTASIS OF PATIENTS WITH NEOPLASIA AND THEIR INFLUENCE ON THE MICROCIRCULATORY BED OF THE LUNGS AND CONTROL BY ANTICOAGULANTS
Vira A. Barilka, Volodymyr L. Matlan, Sofia V. Prymak, Olha O. Shalay, Vasyl L. Novak. SI qInstitute of Blood Pathology and Transfusion Medicine of NAMS of Ukraineq Lviv Ukraine, Lviv, Ukrenia


ANTITHROMBOTIC STEWARDSHIP AND HEALTH EQUITY IN PERIPHERAL ARTERY DISEASE
Kelly M. Rudd1, 2, Kristie K. Roberts1, Cooper M. Hamilton2. 1Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tulsa, OK, USA. 2Oklahoma State University Center for Health Sciences Center College of Osteopathic Medicine, Tahlequah, OK, USA


PLATELET IMMUNOPHENOTYPE INDUCED BY THE SPIKE (S) PROTEIN AND THE RBD DOMAIN OF SARS-COV-2 VIRUS.
Alan Cano-Mendez, Nallely Garcia-Larragoiti, Yesenia Ambriz-Murillo, Patricia Guzman-Cansino, Alejandra Ochoa-Zarzosa, Martha Eva Viveros-Sandoval. Universidad Michoacana de San NicolAis de Hidalgo, Morelia, Mexico


CORRELATION BETWEEN ABO BLOOD TYPES AND DISEASE SEVERITY IN SICKLE CELL ANEMIA: IMPLICATIONS FOR THROMBOSIS AND HEMOSTASIS.
George M Bassey1, Titilope A Adeyemo1, 2, Ann A Ogbenna1, 2, Abiola B Bolarinwa1, Ademola S Adewoyin2, Emmanuel Iyere1. 1Lagos University Teaching Hospital, Lagos, Nigeria. 2College of Medicine University of Lagos, Lagos, Nigeria


THE PREVALENCE OF THROMBOTIC EVENTS REPORTED FOLLOWING SARS-COV2 VACCINE RECEIPT: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY
Jennifer DiRaimo1, Caroline Kruse1, Kate Foster1, Alexandra Kruse1, 2, Howard Liebman3, Craig Kessler4. 1Platelet Disorder Support Association, Cleveland, OH, USA. 2Tulane University School of Medicine, New Orleans, LA, USA. 3Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Norris Comprehensive Cancer Center, Los Angeles, CA, USA. 4Vincent Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA


INVESTIGATING INTER-ASSAY VARIABILITY BETWEEN DOAC CALIBRATED ANTI-FACTOR XA ASSAYS: A SUBSTUDY OF THE PAUSE TRIAL
Ryan Baker1, Rita Selby2, 3, Karen A. Moffat4, 5, Melanie St John5, Alex C. Spyropoulos6, 7, 8, Sam Schulman9, James Douketis9. 1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 2Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. 3Department of Medicine, University of Toronto, Toronto, ON, Canada. 4Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. 5Department of Medicine, McMaster University, Hamilton, ON, Canada. 6The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. 7Institute of Health System Science - The Feinstein Institutes for Medical Research, Manhasset, NY, USA. 8Anticoagulation and Clinical Thrombosis Services, Northwell Health at Lenox Hill Hospital, New York, NY, USA. 9Department of Medicine and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada


CHIEF: A RETROSPECTIVE SELF-CONTROL STUDY OF CHILDREN
Daniel Mashiach1, 2, Patrice Mead1, Kendall Carneiro1, Jemily Malvar1, Guy Young1, 3. 1Childrena, Los Angeles, CA, USA. 2WesternU College of Osteopathic Medicine of the Pacific, Pomona, CA, USA. 3Keck School of Medicine, University of Southern California, Los Angeles, CA, USA


THE EVALUATION OF MRX PT DOAC ASSAY FOR DETECTION OF CLINICALLY RELEVANT FACTOR XA INHIBITOR DRUG LEVELS
Brittany MA Salter1, Karen A Moffat1, 2, 3, Stephen A Carlino3, Liselotte OnelApv4, Sarah Ge1, Marina Atalla1, Raymond Melika1, Saumya Bansal1, Siraj Mithoowani1, Mark Crowther1, 2. 1Department of Medicine, McMaster University, Hamilton, ON, Canada. 2Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 3Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. 4Nordic Biomarker, UmeAy, Sweden


A RETROSPECTIVE STUDY OF ACQUIRED VON WILLEBRAND SYNDROME IN MYELOPROLIFERATIVE NEOPLASMS
Mohammed Al Sharif 1, 2, Brian Harnett 3, Subia Tasneem 1, Brian Leber 4, 5, Christopher Hillis 5, Catherine P. M. Hayward 1, 3, 4. 1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada. 2 Department of Pathology and Laboratory Medicine, King Abdullah Bin Abdulaziz University Hospital, Princess Nourah University, Riyadh, Saudi Arabia. 3 Department of Medicine, McMaster University, Hamilton, ON, Canada. 4 Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada. 5 Hematology/Oncology, Juravinski Cancer Center, Hamilton, ON, Canada


DEVELOPMENT OF A PATIENT REPORTED OUTCOME MEASURE TO STUDY QUALITY OF LIFE IN BLEEDING DISORDER OF UNKNOWN CAUSE
Callie Berkowitz1, Supreet Goraya2, Alice Ma1, Nigel Key1, Angela Stover3. 1Division of Hematology and Blood Research Center, University of North Carolina, Chapel Hill, NC, USA. 2Department of Maternal, Child, and Family Health, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA. 3Department of Health Policy and Management, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA


USING A THROMBODYNAMICS TEST FOR DIAGNOSTICS OF HYPERCOAGULATION IN CANCER PATIENTS AND PREDICTION OF THROMBOEMBOLIC COMPLICATIONS: PRELIMINARY RESEARCH RESULTS.
Irina Dudina1, Ekaterina Koltsova2, 3, Irina Nigmatullina1, Yana Akhmadiyarova1, Olga Kostash1, Anna Chankina1, Daniil Stroyakovskiy1. 1State Budgetary Healthcare Institution Moscow City Oncology Hospital No. 62 of the Moscow City Health Department, Russian Federation, Moscow, 143515, Moskovskaya area, Krasnogorsk urban district, Istra village, building 27, Moscow, Russia. 2Federal State Budgetary Institution Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Health of the Russian Federation, Russian Federation, Moscow, 117198, Samory Machel street, building 1, Moscow, Russia. 3Federal State Budgetary Institution of Science Center for Theoretical Problems of Physico-Chemical Pharmacology, Russian Academy of Sciences, Russian Federation, Moscow, 109029, Srednyaya Kalitnikovskaya street, building 30, Moscow, Russia


COMPARATIVE ANALYSIS OF BLEEDING AND THROMBOTIC RISKS AMONG IMMUNE CHECKPOINT INHIBITORS: INSIGHTS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM
Emily L Paton1, Emma P Deloughery1, 2. 1Oregon Health a Science University, Department of Medicine, Portland, OR, USA. 2Oregon Health a Science University, Department of Medicine, Division of Hematology a Medical Oncology, Portland, OR, USA


ACQUIRED HEMOPHILIA SECONDARY TO THE TRANSPLANTATION OF HEMATOPOIETIC PROGENITORS. A SYSTEMATIC REVIEW
Rafael Pichardo-Rodriguez1, Cristhian Gonzales- Rospigliosi1, Dalia Pimentel-Ramirez1, Aracely Carrasco-Espinoza1, Lara Vela-Rojas1, Diana-Cristina RamAsrez-Meyhuay1, Jhony A. De La Cruz-Vargas1, Alfredo Wong Chang2, Cristobal Frutos3. 1Instituto de Investigaciones en Ciencias BiomAcdicas (INICIB). Universidad Ricardo Palma, Lima, Peru. 2Unidad de Trasplante de MAcdula A, Lima, Peru. 3Instituto de PrevisiA³n Social, Asuncion, Paraguay


EFFECT OF ACUTE DEEP VEIN THROMBOSIS IN PATIENTS WITH LUNG CANCER IN ACUTE DEEP VEIN THROMBOSIS (DVT): A STUDY OF THE NATION INPATIENT SAMPLE
Maria Cristina Cuartas- Mesa, Nana Yaa Ampaw, Edwin Gwira- Tamattey, Enrique Martinez- Trevino, Alejandro Nieto- Dominguez , Ekrem Turk . John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA


GATHERING AND DISSEMINATING STANDARDIZED GENE THERAPY DATA - THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY
Barbara A. Konkle1, Flora Peyvandi2, Mayss Naccache3, Wolfgang Miesbach4, Brian O'Mahony5, Steven W. Pipe6, Mark W. Skinner7, Donna Coffin3, Glenn F. Pierce3. 1University of Washington, Seattle, WA, USA. 2Department of Pathophysiology and Transplantation, UniversitAn degli Studi di Milano, Milan, Italy. 3World Federation of Hemophilia, Montreal, QC, Canada. 4University Hospital Frankfurt, Frankfurt, Germany. 5Irish Haemophilia Society, Dublin, Ireland. 6University of Michigan, Ann Arbor, MI, USA. 7Institute for Policy Advancement Ltd, Washington, DC, USA


PREDICTING PULMONARY EMBOLISM IN PATIENTS WITH DEEP VENOUS THROMBOSIS IN THE EMERGENCY DEPARTMENT: A QUANTITATIVE D-DIMER DIAGNOSTIC APPROACH FROM A HOSPITAL IN MEXICO CITY
Oscar A Lopez Ramos1, David G Gonzalez Sanchez 2, Oliver A Gomez-Gutierrex2, Hector Segura Marin2, Andrea Rojas Guevara 1, Arely Gayosso Godinez 1. 1Hospital EspaApol, Mexico City, Mexico. 2Tecnologico de Monterrey, Monterrey, Mexico

3:00 - 3:45 PM
POSTERS/EXHIBITS/BREAK
POSTERS/EXHIBITS/BREAK (click to view)
Riverwalk AB


A1. ANTICOAGULATION CLINICS


301

NOVEL POINT-OF-CARE (POC) PLATFORM FOR DIRECT ORAL ANTICOAGULANTS (DOAC) AND VITAMIN K ANTAGONISTS (AVK) TESTING: MICRODOAC AND MICROINR ASSAYS
Tamara Montes, Mikel Santiago, Irene Mijangos. RaD Department, iLine Microsystems S. L, San SebastiAin/Donostia, Spain


A2. PLATELET ACTIVATION AND BIOCHEMISTRY


302

RED BLOOD CELL HAEMOLYSIS AND PLATELET ACTIVATION : THE FORGOTTEN PLAYERS OF HYPERCOAGULABILITY
Neha Thomas, Stipo Jurcevic. University of Westminster, London, United Kingdom


A4. DISORDERS OF PLATELET NUMBER OR FUNCTION


303

HMB-001 FOR PROPHYLACTIC TREATMENT OF GLANZMANN THROMBASTHENIA: PHASE 1/2 TRIAL INSIGHTS
Suthesh Sivapalaratnam1, 2, Gillian Lowe3, Ashley Gosnell4, Ulrike Lorch5, Jigar Amin4, Catherine Rea4. 1Queen Mary University of London, London, United Kingdom. 2Barts Health NHS Trust, London, United Kingdom. 3Comprehensive Care Haemophilia Centre, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom. 4Hemab Therapeutics, Cambridge, MA, USA. 5Richmond Pharmacology, London, United Kingdom


A5. BLOOD COAGULATION AND FIBRINOLYTIC FACTORS


304

INVESTIGATING THE RELATIONSHIP BETWEEN D DIMER LEVELS AND VISCOELASTIC CHARACTERISTICS OF BLOOD CLOTS
Eli J Foster, Nathaniel Hai, Seemantini K Nadkarni. Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA


305

TRANSFUSION TRENDS IN THE OBSTETRIC POPULATION WITH ANALYSIS OF A SOFT STOP TRANSFUSION EMR ALERT
Maren Plant1, Sophia Cordes1, Caroline Bereuter1, Jaclyn Phillips1, Xiomara Fernandez2, Homa Ahmadzia1. 1Department of Obstetrics and Gynecology, George Washington University, Washington, DC, USA. 2Department of Pathology, George Washington University, Washington, DC, USA


A6. DISORDERS OF COAGULATION OR FIBRINOLYSIS


306

THE BURDEN OF HEMOPHILIA IN THE US: METHODS AND RESULTS FROM THE COST OF HEMOPHILIA: A SOCIOECONOMIC SURVEY (CHESS) US (2022)
Randall Curtis1, Maria Elisa Mancuso2, 3, Enrico Ferri Grazzi4, Donna Coffin5, Brian O'Mahony6, 7, Clive Smith8, DaniAcl Anibal GarcAsa Diego9, Matteo Arzenton10, Thomas SanniAc11, Fiona Brennan12, Tom Burke4, 13, Sarah Brighton4. 1Hematology Utilization Group Study (HUGS), Walnut Creek, CA, USA. 2Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Italy. 3Humanitas University, Pieve Emanuele, Milan, Italy. 4HCD Economics, Knutsford, United Kingdom. 5World Federation of Hemophilia, Montreal, QC, Canada. 6Irish Haemophilia Society Ltd, Dublin, Ireland. 7Trinity College, Dublin, Ireland. 8The Haemophilia Society, London, United Kingdom. 9FederaciA³n EspaApola de Hemofilia (FedHemo), Madrid, Spain. 10Italian Federation of Haemophilia Associations (FedEmo), Rome, Italy. 11Association FranAsaise des HAcmophiles (AFH), Paris, France. 12Faculty of Health and Social Care, University of Chester, Chester, United Kingdom


307

HEMOSTATIC OUTCOME OF SURGICAL PROCEDURES IN PATIENTS WITH HEMOPHILIA RECEIVING CONCIZUMAB PROPHYLAXIS: DATA FROM THE PHASE 3 EXPLORER7 AND EXPLORER8 TRIALS
Matthew Evans1, Anthony K. C. Chan2, Chris Barnes3, Mary Mathias4, Silvia Linari5, Francisco-JosAc LA³pez-Jaime6, Lone Hvitfeldt Poulsen7, Julien Bovet8, Jan Odgaard-Jensen8, Tadashi Matsushita9, Emily K. Waters10. 1Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. 2McMaster Childrena, Hamilton, ON, Canada. 3Royal Childrena, Victoria, Australia. 4Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. 5Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy. 6Hospital Regional Universitario de MAilaga, MAilaga, Spain. 7The Haemophilia Centre, Department of Haematology, Aarhus University Hospital, Aarhus, Denmark. 8Novo Nordisk A/S, SAcborg, Denmark. 9Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. 10Novo Nordisk Inc, Plainsboro, NJ, USA


308

ATHN TRANSCENDS - HEMOPHILIA GENE THERAPY OUTCOMES ARM: A LONG-TERM FOLLOW-UP STUDY ON SAFETY AND EFFECTIVENESS OF GENE THERAPY IN PEOPLE WITH HEMOPHILIA
Staber Janice1, Blanca Salazar2, Roberto Guillen-Gonzalez2, Michael Recht3, 4, Tammuella Chrisentery-Singleton5, Ulrike Reiss6. 1Iowa Hemophilia and Thrombosis Center University of Iowa Stead Family Childrena, Iowa City, IA, USA. 2CSL Behring, King of Prussia, PA, USA. 3National Bleeding Disorders Foundation, New York, NY, USA. 4Yale University School of Medicine, New Haven, CT, USA. 5American Thrombosis and Hemostasis Network, Rochester, NY, USA. 6Hemophilia Treatment Center St. Judea, Memphis, TN, USA


309

A PHASE 3, RANDOMIZED, ACTIVE-CONTROL STUDY OF FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE VERSUS FROZEN PLASMA IN BLEEDING ADULT CARDIAC SURGERY PATIENTS
Keyvan Karkouti1, 2, Jeannie Callum3, 4, Kenichi Tanaka5, Deep Grewal2, Cristina Solomon6, Sigurd Knaub6, Sylvia Werner7, Gita Pezeshki7, Jerrold H. Levy8. 1University of Toronto, Toronto, ON, Canada. 2University Health Network, Toronto, ON, Canada. 3Queena, Kingston, ON, Canada. 4Kingston Health Sciences Centre, Kingston, ON, Canada. 5University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 6Octapharma AG, Lachen, Switzerland. 7Octapharma USA, Paramus, NJ, USA. 8Duke University School of Medicine, Durham, NC, USA


310

VITAMIN D DEFICIENCY IN PERSONS WITH BLEEDING DISORDERS - A SINGLE CENTER EXPERIENCE
Dan Leary, Mindy Simpson, Lisa Boggio. Rush Hemophilia and Thrombophilia Center, Chicago, IL, USA


311

GENOMIC VARIATIONS IN FACTOR VII DEFICIENCY PREDISPOSING TO THROMBOPHILIA: A CASE OF SINUS VENOUS THROMBOSIS IN A PATIENT WITH FACTOR VII DEFICIENCY
Aaron C. Lobo 1, Paridhi Ghai1, Fabricio M Webber1, David H. Witt2. 1Bridgeport Hospital/Yale New Haven Health, Bridgeport, CT, USA. 2Yale Smilow Cancer Center/Yale school of Medicine, Trumbull, CT, USA


312

EMICIZUMAB PROPHYLAXIS FOR THE TREATMENT OF INFANTS WITH SEVERE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: PRIMARY ANALYSIS OF THE HAVEN 7 STUDY
Steven W. Pipe1, Peter Collins2, Christophe Dhalluin3, Gili Kenet4, 5, Christophe Schmitt3, Muriel Buri3, VAsctor JimAcnez-Yuste6, Flora Peyvandi7, 8, Guy Young9, Johannes Oldenburg10, Maria Elisa Mancuso11, 12, Kaan Kavakli13, Anna Kiialainen3, Markus Niggli3, Tiffany Chang14, Michaela Lehle 3, Karin Fijnvandraat15. 1University of Michigan, Ann Arbor, MI, USA. 2School of Medicine, Cardiff University, Cardiff, United Kingdom. 3F. Hoffmann-La Roche Ltd, Basel, Switzerland. 4Sheba Medical Center, Ramat Gan, Israel. 5Tel Aviv University, Tel Aviv, Israel. 6Hospital Universitario La Paz-IdiPaz, Universidad AutA³noma, Madrid, Spain. 7Fondazione IRCCS Caa, Milan, Italy. 8UniversitAn degli Studi di Milano, Milan, Italy. 9Childrena, Los Angeles, CA, USA. 10Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany. 11IRCCS Humanitas Research Hospital, Rozzano, Italy. 12Humanitas University, Pieve Emanuele, Milan, Italy. 13Ege University Faculty of Medicine Children's Hospital, Izmir, Turkey. 14Spark Therapeutics, Inc, San Francisco, CA, USA. 15University of Amsterdam, Amsterdam, Netherlands


313

A MULTI-YEAR FOLLOW-UP STUDY OF FIDANACOGENE ELAPARVOVEC GENE THERAPY FOR HEMOPHILIA B
Benjamin J. Samelson-Jones1, 2, Lindsey A. George1, 2, John E. J. Rasko3, 4, Adam Giermasz5, Jerome M. Teitel6, Catherine E. McGuinn7, Jonathan M. Ducore5, Sharon Pennington8, Katherine A. High2, Jeremy Rupon9, Francesca Biondo10, Annie Fang11, Lynne M. Smith9, Matko Kalac11, Amit Chhabra11, Frank Plonski9. 1Childrena, Philadelphia, PA, USA. 2Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 3Department of Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney, Australia. 4Gene and Stem Cell Therapy Program, Centenary Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia. 5Hemophilia Treatment Center, University of California Davis, Sacramento, CA, USA. 6St. Michaela, Toronto, ON, Canada. 7Weill Cornell Medicine, New York, NY, USA. 8Mississippi Center for Advanced Medicine, Madison, MS, USA. 9Pfizer Inc, Collegeville, PA, USA. 10Pfizer Srl, Rome, Italy. 11Pfizer Inc, New York, NY, USA


314

EMERGENCY DEPARTMENT UTILIZATION IN A PATIENT COHORT WITH HEMOPHILIA: A SINGLE CENTRE EXPERIENCE
Kelsey Uminski1, 2, Natalia Rydz1, 2, Dawn Goodyear1, 2. 1Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary, Calgary, AB, Canada. 2Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Calgary, AB, Canada


A8. ANTITHROMBOTIC THERAPY


315

DUAL DIRECT ORAL ANTICOAGULANT THERAPY IN CHALLENGING THROMBOSIS: A CASE SERIES
Heather McPhaden1, Chornenki Nicholas1, Peterson Erica1, Lai Chieh Min Benjamin1, 2, Lee Agnes1. 1The University of British Columbia, Department of Medicine, Division of Hematology, Vancouver, BC, Canada. 2The University of British Columbia Centre for Blood Research, Vancouver, BC, Canada


316

RECURRENT VENOUS THROMBOEMBOLISM IN A SYMPTOMATIC HEMOPHILIA A CARRIER
Natalie/A Montanez1, 3, Joanna/M Larson1, 3, Miguel/A Escobar1, 2, 3. 1University of Texas Health Science Center of Houston, McGovern Medical School, Department of Pediatrics, Houston, TX, USA. 2University of Texas Health Science Center of Houston, McGovern Medical School, Department of Internal Medicine, Houston, TX, USA. 3Gulf States Hemophilia and Thrombophilia Center, Houston, TX, USA


317

A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF HUMAN PLASMA DERIVED ANTITHROMBIN (ATENATIV) IN HEPARIN-RESISTANT CARDIAC SURGERY PATIENTS
Cristina Solomon1, Catrin Argyle1, Jerrold H. Levy2, Sylvia Werner1. 1Octapharma AG, Lachen, Switzerland. 2Duke University School of Medicine, Durham, NC, USA


318

AN IMPLEMENTATION DILEMMA: REJECTION OF THROMBOPROPHYLAXIS RECOMMENDATIONS IN THE CHILDREN'S LIKELIHOOD OF THROMBOSIS (CLOT) TRIAL
Shannon C. Walker, Benjamin French, Ryan P. Moore, Henry J. Domenico, C. Buddy Creech, Amanda S. Mixon, Daniel W. Byrne, Allison P. Wheeler. Vanderbilt University Medical Center, Nashville, TN, USA


A9. INFORMATIONAL ABSTRACT (POSTER ONLY)


319

OVERCOMING DISTANCE AND TRAVEL BARRIERS FOR VIRGINIA BLEEDING DISORDERS TREATMENT CENTERS: A COMPREHENSIVE NEEDS ASSESSMENT
Erika J Martin, Lauren C Dunn, Katherine L Bains, Janice G Kuhn. Virginia Commonwealth University, Richmond, VA, USA


320

DOAC'S IN THE ELDERLY
Abhinav Paknikar1, Keerti Chakravarthy1, Fakiha Siddiqui2, Atul Laddu1, Jawed Fareed2, Aarushi Dua1, Anish Joshi1. 1Global Thrombosis Forum, Suwanee, GA, USA. 2Loyola University, Chicago, IL, USA

3:45 - 5:15 PM
THROMBOSIS
HEALTH CARE INEQUITITY IN THE TREATMENT OF VTE
Chair/Organizer: Anne Rose, Vinai Bhagirath
Sheraton Ballroom I-II


3:45

DISPARITIES IN ANTICOAGULATION CARE ACROSS THE SPECTRUM
Sara Vasquez.


4:15

TREATMENT OF VTE IN RURAL AMERICA
Jennifer Young.


4:45

MATERNAL MORTALITY AND PULMONARY EMBOLISM IN MINORITY POPULATIONS
Leslie Lake.

3:45 - 5:15 PM
HEMOSTASIS / LABORATORY
LAB SUPPORT OF CLINICAL DECISION-MAKING IN THE CRITICALLY ILL BLEEDING PATIENT
Chair/Organizer: Marian Rollins-Raval, Allison Wheeler
Chicago Ballroom VII


3:45

HOW THE LAB CAN SUPPORT CLINICAL DECISION-MAKING IN ACUTE CRITICAL BLEEDING
Nathan Nielsen.


4:15

REVIEW OF THE USE OF CONCENTRATED CLOTTING FACTORS VERSUS BLOOD PRODUCTS
Laura Downey.


4:45

COAGULATION BIOMARKERS AND LABORATORY SUPPORT OF CRITICALLY ILL PATIENTS
Sabrina Racine-Brzostek.

3:45 - 5:15 PM
BASIC SCIENCE
TAKE A HIKE MICKEY- NOVEL T&H INSIGHTS FROM NON-MURINE ANIMALS
Chair/Organizer: Bobby Lee, Anna Dahlgren
Sheraton Ballroom IV-V


3:45

MULTISPECIES ANALYSIS OF THE ERAD PATHWAY IN PLATELET FUNCTION
Anna Dahlgren.


4:15

DECIPHERING PLATELET COLD STORAGE LESION IN HIBERNATING RODENTS
Scott Cooper.


4:45

DISCOVERING NOVEL PRO-COAGULANT AGENTS FROM SNAKE VENOM
Raymond Adili.

5:30 - 6:30 PM
SATELLITE SYMPOSIUM
CLINICAL & PATIENT PERSPECTIVE: A TREATMENT FOR ADULTS WITH ACUTE HEPATIC PORPHYRIA, INCLUDING ACUTE INTERMITTENT PORPHYRIA (SPONSORED BY: ALNYLAM PHARMACEUTICALS)
Chicago Ballroom VI

Acute hepatic porphyria (AHP) is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. Led by Dr. Angelika Erwin, a consultant of Alnylam Pharmaceuticals, this presentation will provide a disease overview and review the clinical profile of a treatment for adults with AHP, featuring Phase 3 Study results and open-label extension data. Attendees will also hear from an AHP patient who will share their experience with the disease and treatment. Please join Alnylam Pharmaceuticals and Dr. Erwin to learn more about this treatment for adults with AHP. Dinner will be provided for attendees.



GENE THERAPY FOR HEMOPHILIA B: SHARING EXPERIENCES IN REAL-WORLD SETTINGS (SPONSORED BY: CSL BEHRING)
Chicago Ballroom IX-X

Despite meaningful improvements in treatment for hemophilia B, there remains a need for new therapeutic options that will reduce bleeds, reduce or eliminate the need for routine factor IX prophylaxis, and provide long-term benefits of sustained factor IX activity levels. The first ever FDA-approved gene therapy for hemophilia B is designed to reduce the burden of disease on patients lives by addressing these unmet needs. Join our educational product theater session as a team of hemophilia B experts discuss the clinical data and the patient and HCP journey towards treatment as well as share their clinical experiences with gene therapy for hemophilia B. Continuing education credits will not be offered for this program.


7:00 - 8:00 PM
SATELLITE SYMPOSIUM
UNLOCKING THE NEXT STEP IN GENE THERAPY FOR HEMOPHILIA: THE END OF THE BEGINNING? (SPONSORED BY CSL BEHRING)
On-Demand/Online